<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ijms-22-00265-t002" orientation="portrait" position="float">
 <object-id pub-id-type="pii">ijms-22-00265-t002_Table 2</object-id>
 <label>Table 2</label>
 <caption>
  <p>Protective and therapeutic potential of taro corms.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Property</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Taro Corm Preparation</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Bioactive Compound Class</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Active Principle</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Screening</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Biological Effect of Its Derivatives</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Reference</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Origin of Taro Corms</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#E7E6E6" colspan="1">
     <bold>Antitumoral/Antimetastatic</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">poi extract</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of rat YYT colon cancer cells (nearly 80–90%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B41-ijms-22-00265" ref-type="bibr">41</xref>]
    </td>
    <td rowspan="5" align="center" valign="middle" style="border-left:solid thin;border-bottom:solid thin" colspan="1">USA</td>
   </tr>
   <tr>
    <td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Crude taro extract</td>
    <td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Protein</td>
    <td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Tarin</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of murine breast cancer cell lines: 66.1 (54%), 410.4 (24%) and EpH4 (21%)</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[
     <xref rid="B42-ijms-22-00265" ref-type="bibr">42</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of human breast cancer cell lines: MCF-7 (65%), MDA-MB-231 (26%), MCF10A (31%)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Reduction of PGE2 release (63%) and mRNA COX-1/2 expression</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition lung and heart colonization by murine lineages 66.1 and 410.4 (85–99% reduction)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of human hepatoma HepG2 cells (25%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B43-ijms-22-00265" ref-type="bibr">43</xref>]
    </td>
    <td align="center" valign="middle" style="border-left:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">China</td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Tarin nano-liposomal capsules</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of human breast cancer MDA-MB-231 (41%)</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[
     <xref rid="B44-ijms-22-00265" ref-type="bibr">44</xref>]
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-left:solid thin;border-bottom:solid thin" colspan="1">Brazil</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of human Glioblastoma U87 MG lineage (65%)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Polysaccharide</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Taro-4-I</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of lung colonization by murine B16BL6 melanoma cells (96.2%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B45-ijms-22-00265" ref-type="bibr">45</xref>]
    </td>
    <td align="center" valign="middle" style="border-left:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Korea</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Ethanolic crude taro extract</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of various adult T-cells leukemia (ATL) lineages IC50 from 25 to 106.9 μg/mL</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B46-ijms-22-00265" ref-type="bibr">46</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japan</td>
   </tr>
   <tr>
    <td rowspan="20" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#E7E6E6" colspan="1">
     <bold>Immunomodulatory</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">poi extract</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Proliferation of spleen cells (T, B and NK cells)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B41-ijms-22-00265" ref-type="bibr">41</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
   </tr>
   <tr>
    <td rowspan="19" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Crude taro extract</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Polysaccharide</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Taro-4-I</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Activation of complement system by alternative and classical pathways</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">[
     <xref rid="B45-ijms-22-00265" ref-type="bibr">45</xref>]
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Korea</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Release of IL-6, IL-12 and TNF-α by macrophages</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Activation of NK cells cytotoxicity against Yac-1 cells</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">TPS-1 and TPS-2</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Activation of macrophage (RAW 264.7) with releasing of NO, IL-6 and TNF-α</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B47-ijms-22-00265" ref-type="bibr">47</xref>]
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">China</td>
   </tr>
   <tr>
    <td rowspan="11" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Protein</td>
    <td rowspan="11" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Tarin</td>
    <td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Cytokine expression IL-2, IL1β, INF-γ and TNF-α</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">[
     <xref rid="B43-ijms-22-00265" ref-type="bibr">43</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Total spleen cells proliferation</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Proliferation of mice spleen cells</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B48-ijms-22-00265" ref-type="bibr">48</xref>]
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Brazil; Philippines; China</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Proliferation of mice bone marrow cells</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B49-ijms-22-00265" ref-type="bibr">49</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Protection of BM mice granulocytic progenitor cells</td>
    <td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">[
     <xref rid="B50-ijms-22-00265" ref-type="bibr">50</xref>]
    </td>
    <td rowspan="11" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Brazil</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Promotion of repopulation of BM granulocytic Gr1+ cells</td>
   </tr>
   <tr>
    <td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Attenuation of leukopenia in immunosuppressed mice</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Enhancement of BM granulocytic progenitors</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Proliferation/differentiation into mature BM granulocytes</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Protection of BM erythroid cells from CY-cytotoxicity</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">3.3-fold enhancement on 5th day (mice spleen cells)
     <break/>4.1-fold enhancement on 5th day (mice Spleen B lymphocytes)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B48-ijms-22-00265" ref-type="bibr">48</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">-</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">-</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Proliferation of total mice spleen cells in 5 days</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">[
     <xref rid="B51-ijms-22-00265" ref-type="bibr">51</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Proliferation of B220+ lymphocytes from mice spleen in 5 or 10 days</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Proliferation of total mice bone marrow cells in 10 days</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Proliferation of total mice spleen cells</td>
   </tr>
   <tr>
    <td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#E7E6E6" colspan="1">
     <bold>Anti-hyperglycemic</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Taro flour</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Flavonoid; Alkaloid; saponin; tannin</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">-</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Decrease of blood glucose on hyperglycemic rats Amelioration of biochemical parameters in the urine Amelioration of liver, hepatic function and, body weight</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B52-ijms-22-00265" ref-type="bibr">52</xref>,
     <xref rid="B53-ijms-22-00265" ref-type="bibr">53</xref>,
     <xref rid="B54-ijms-22-00265" ref-type="bibr">54</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nigeria</td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Methanolic extract of taro flour</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Alkaloid; flavonoid; steroid</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Improvement of oral glucose tolerance</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">[
     <xref rid="B55-ijms-22-00265" ref-type="bibr">55</xref>]
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bangladesh</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Decrease of blood glucose levels (35.8%)</td>
   </tr>
   <tr>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">mucilage-rich extract from crude taro flour</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Neutral sugar; protein, polyphenols</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">-</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of alpha-amylase IC
     <sub>50</sub> = 2.23 ± 0.24 mg/mL
    </td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">[
     <xref rid="B56-ijms-22-00265" ref-type="bibr">56</xref>]
    </td>
    <td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">South Africa</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of alpha-glucosidase IC
     <sub>50</sub> = 1.60 ± 0.17 mg/mL
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Ex vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibits glucose absorption in isolated rat jejunum IC
     <sub>50</sub> = 1.82 ± 0.24 mg/mL
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Enhances glucose uptake by rat psoas muscle GU
     <sub>50</sub> = 0.78 ± 0.13 mg/mL
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Extract from defatted crude taro flour</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Protein</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">A-1 and B-2</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of human pancreatic (28.5 and 48.5%) and salivary alpha-amylase (62 and 56%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B57-ijms-22-00265" ref-type="bibr">57</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#E7E6E6" colspan="1">
     <bold>Anti-hypercholesterolemic or Anti-hyperlipidemic</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Taro flour</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Flavonoid; Alkaloid; saponin; tannin</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">-</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Decrease of total cholesterol, VLDL-, LDL-cholesterol, triacylglycerol, atherogenic and coronary risk.
     <break/>Increase of HDL-cholesterol
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">[
     <xref rid="B52-ijms-22-00265" ref-type="bibr">52</xref>,
     <xref rid="B54-ijms-22-00265" ref-type="bibr">54</xref>]
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nigeria</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Reduction of serum pancreatic lipase levels</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Extract from cooked taro flour</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Reduction of total blood cholesterol (36.41%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B58-ijms-22-00265" ref-type="bibr">58</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Indonesia</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">mucilage-rich extract from crude taro flour</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Neutral sugar; protein, polyphenols</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">-</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition of pancreatic lipase IC
     <sub>50</sub> = 1.63 ± 0.15 mg/mL
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B56-ijms-22-00265" ref-type="bibr">56</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">South Africa</td>
   </tr>
   <tr>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Ethanolic extract from crude taro</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Lipid</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Extract</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Inhibition (55%) of human lanosterol synthase (hOSC)</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">[
     <xref rid="B59-ijms-22-00265" ref-type="bibr">59</xref>]
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Japan</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">MGDG 1-3</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">Inhibition (28–67%) of human lanosterol synthase (hOSC)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">DGDG 1-4</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Mucilage-rich extract from taro flour</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Polysaccharide</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Arabinogalactan</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Decrease lipid levels in serum and tissues; decrease synthesis/secretion of apoB-containing lipoproteins, mainly VLDL, by hepatocytes.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B60-ijms-22-00265" ref-type="bibr">60</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India</td>
   </tr>
   <tr>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#E7E6E6" colspan="1">
     <bold>Anti-mutagenic</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Dietary fiber-rich extract from crude taro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Polysaccharide</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">-</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Avoid mutation induced by DNP (87%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B61-ijms-22-00265" ref-type="bibr">61</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Samoa</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Crude taro extract</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Avoid mutation by UV radiation with ID
     <sub>50</sub> = 0.6 mg/plate
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B62-ijms-22-00265" ref-type="bibr">62</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japan</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Heptane extract from cooked taro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Avoid mutation by IQ with IC
     <sub>50</sub> = 200–500 μg/plate
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B63-ijms-22-00265" ref-type="bibr">63</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New Zealand</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#E7E6E6" rowspan="1" colspan="1">
     <bold>Antioxidant</bold>
    </td>
    <td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">See 
     <xref rid="ijms-22-00265-t003" ref-type="table">Table 3</xref>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>(
    <bold>nearly 80</bold>–
    <bold>90%</bold>)—Calculated percentage. 
    <bold>NK</bold>—natural killer. 
    <bold>Yac-1 cells</bold>—mouse lymphome cell line sensitive to NK cells. 
    <bold>NO</bold>—nitric oxide. 
    <bold>BM</bold>—bone marrow. 
    <bold>CY</bold>—cyclophosphamide. 
    <bold>MGDG</bold>—monogalactosyldiacylglycerols. 
    <bold>DGDG</bold>—digalactosyldiacylglycerols. 
    <bold>DNP</bold>—1,8 dinitropyrene. 
    <bold>IQ</bold>—heterocyclic amine 2-amino-3-methylimidazo [4,5-f ]quinoline. 
    <bold>PGE2</bold>—prostaglandin E2. 
    <bold>COX 1/2</bold>—cyclooxygenase 1 and 2. 
    <bold>TNF-α</bold>—tumour necrosis factor alpha. 
    <bold>IL</bold>—interleukin. 
    <bold>INF</bold>-
    <bold>γ</bold>—interferon gamma. 
    <bold>VLDL</bold>—very low-density lipoprotein. 
    <bold>HDL</bold>—high-density lipoprotein. 
    <bold>LDL</bold>—low-density lipoprotein. 
    <bold>IC50</bold>—half maximal inhibitory concentration. 
    <bold>GU50</bold>—glucose uptake. 
    <bold>hOSC</bold>—human oxidosqualene--lanosterol cyclase. 
    <bold>apoB</bold>—apolipoprotein B. 
    <bold>ID50</bold>—inhibitory dose for 50% of relative mutagenic activity.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
